{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-248162","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.616368+00:00","generated_at":"2026-05-30T07:23:33.083768+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Karyopharm changes co-primary endpoint for Phase 3 SENTRY trial to Abs-TSS; increases sample size to 350","bullets":["Co-primary endpoint changed from TSS50 to Abs-TSS following FDA alignment; SVR35 remains co-primary.","Phase 1 Selinexor+ruxolitinib data showed 79% SVR35 (n=14) and 18.5-point average Abs-TSS improvement (n=9) at week 24.","Total sample size increased to ~350 patients to improve statistical power; top-line data still expected in 2H 2025.","Safety profile remains consistent with no new signals; change supported by key investigators and MPN Research Foundation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-248162","json":"https://secwatch.observer/filing/0001193125-24-248162.json","markdown":"https://secwatch.observer/filing/0001193125-24-248162.md","text":"https://secwatch.observer/filing/0001193125-24-248162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524248162/0001193125-24-248162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524248162/d891084d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:23:33.083768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}